Proteomics techniques have improved substantially in the past decade, and this has allowed researchers to screen various types of samples, including formalin-fixed paraffin-embedded tissue samples (see the Science and Society article on page 646), for changes in the cancer proteome that could be used to classify patients. However, the need for effective validation and standardization of procedures to improve reproducibility, sensitivity and specificity is impeding the translation of biomarkers to the clinic. As discussed on page 605, this process might be improved through the use of established clinical assays to detect biomarkers. In addition, the Timeline article on page 652 suggests that the cancer proteome could be better characterized and translated to the clinic through large collaborative projects. 
